Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
Li H, Zhao L, Sun Z, Yao Y, Li L, Wang J, Hua T, Ji S, Wang S, Cheng H, Shi M, Li Z, Zeng L, Wu Q, Qiao J, Chen C, Zheng J, Cao J, Xu K.
Li H, et al. Among authors: shi m.
Front Immunol. 2022 Oct 18;13:1019548. doi: 10.3389/fimmu.2022.1019548. eCollection 2022.
Front Immunol. 2022.
PMID: 36330523
Free PMC article.
Clinical Trial.